Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 6/20 | 0.66 |
| ▸ | YTHDC1 | Q96MU7 | 3/20 | 0.62 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.45 |
| ▸ | CDK2 | P24941 | 2/20 | 0.45 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | KCNN2 | Q9H2S1 | 1/20 | 0.36 |
| ▸ | KCNN3 | Q9UGI6 | 1/20 | 0.36 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29426225 | 0.82 | CDK1 (0.68) | CDK1YTHDC1CCNE1CDK2CCNE2 | |
| SCHEMBL183035 | 0.82 | CDK1 (0.68) | CDK1YTHDC1CCNE1CDK2CCNE2 | |
| SCHEMBL790146 | 0.80 | CDK1 (0.46) | CDK1YTHDC1CCNE1CDK2ADORA2A | |
| SCHEMBL129921 | 0.79 | CDK1 (1.00) | CDK1YTHDC1ADORA2AADORA1 | |
| SCHEMBL10026393 | 0.78 | CDK1 (0.41) | CDK1YTHDC1CDK2ADORA2AADORA1 | |
| SCHEMBL16481592 | 0.77 | CDK1 (0.43) | CDK1YTHDC1CCNE1CDK2CCNE2 | |
| SCHEMBL10148680 | 0.77 | CDK1 (0.57) | CDK1YTHDC1CCNE1CDK2ADORA2A | |
| SCHEMBL19978922 | 0.77 | CDK1 (0.60) | CDK1YTHDC1CCNE1CDK2CCNE2 | |
| SCHEMBL19112004 | 0.77 | CDK2 (0.55) | CDK1CCNE1CDK2CCNE2ADORA2A | |
| SCHEMBL13828304 | 0.77 | CDK1 (0.60) | CDK1YTHDC1CCNE1CDK2CCNE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3728282-B1 | 2'3' CYCLIC DINUCLEOTIDES WITH PHOSPHONATE BOND ACTIVATING THE STING ADAPTOR PROTEIN | INST OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR V V I (CZ) | 2023-11-22 | — | — | EP | disclosed |
| US-20230234954-A1 | COMPOUND USED AS RET KINASE INHIBITOR AND APPLICATION THEREOF | TYK MEDICINES, INC. (CN) | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234954-A1 | COMPOUND USED AS RET KINASE INHIBITOR AND APPLICATION THEREOF | RET, ROR1, FGFR3 | CDK1 656/4885YTHDC1 4091/4885CCNE1 2236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.